THURSDAY, Aug. 2 (HealthDay News) -- In patients with coronary heart disease, aerobic exercise and the antidepressant sertraline are both associated with reduced depressive symptoms when compared to placebo, and they both tend to improve heart rate variability, according to a study published online Aug. 1 in the Journal of the American College of Cardiology.
James A. Blumenthal, Ph.D., from the Duke University Medical Center in Durham, N.C., and associates investigated the efficacy of exercise and antidepressant medication in reducing depression symptoms in 101 outpatients with coronary heart disease and elevated depression symptoms. Participants were randomly allocated to four months of aerobic exercise (three times per week), sertraline, or placebo. In addition, cardiovascular biomarker levels were assessed.
At 16 weeks, the researchers found that all groups showed improvement on the Hamilton Rating Scale for Depression scores. Larger reductions were achieved by patients in the aerobic exercise and sertraline groups, versus placebo (P = 0.034), with no significant difference noted between the exercise and sertraline groups (P = 0.607). Greater reductions in heart rate variability tended to be seen with both exercise and sertraline, compared with placebo (P = 0.052), with exercise tending to result in greater reductions than sertraline (P = 0.093).
"Both exercise and sertraline resulted in greater reductions in depressive symptoms compared to placebo in patients with coronary heart disease," the authors write. "Evidence that active treatments may also improve cardiovascular biomarkers suggests that they may have a beneficial effect on clinical outcomes as well as on quality of life."
One author disclosed financial ties to pharmaceutical companies, including Pfizer, which provided the study medication and placebo.